MannKind Corporation (MNKD) Shares are Up 1.78%

MannKind Corporation (MNKD) has been under a strong bear grip, hence the stock is down -2.26% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.72% in the past 1 week. The stock has risen by 1.78% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.25% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 1.21% and the 50-Day Moving Average is 5.15%. MannKind Corporation (NASDAQ:MNKD): stock turned positive on Friday. Though the stock opened at $0.96, the bulls momentum made the stock top out at $1 level for the day. The stock recorded a low of $0.9592 and closed the trading day at $0.9974, in the green by 2.46%. The total traded volume for the day was 1,573,956. The stock had closed at $0.9735 in the previous days trading.


The company Insiders own 0.94% of MannKind Corporation shares according to the proxy statements. Institutional Investors own 18.84% of MannKind Corporation shares.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Companys product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Companys Technosphere powders are -based on the Companys fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *